Informations

Patient Characteristics The trial included 1,059 patients randomized into three treatment arms: nivolumab monotherapy, nivolumab plus ipilimumab, and investigator’s choice chemotherapy (mFOLFOX6 or FOLFIRI with or without bevacizumab or cetuximab).…

The 2025 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2025) has already taken place in San Francisco, USA. This globally renowned academic event brought together top oncology scholars to jointly explore the cutting-edge breakthroughs and future directions in the field of genitourinary oncology.In this insightful exchange, Dr. Xuefeng Qiu from…

With the rapid advancement of ADC-based combination immunotherapies globally, the treatment landscape for advanced urothelial carcinoma has undergone a dramatic transformation, leading to multiple updates in clinical guidelines. This year’s ASCO Genitourinary Cancers Symposium (ASCO GU) was held from February 13–15 in San Francisco, where Professor Jun Guo from Peking University Cancer Hospital led a…

The MARGOT/TBCRC052 trial, presented at SABCS 2024, explored the efficacy of margetuximab + paclitaxel + pertuzumab (TMP) versus the standard trastuzumab + paclitaxel + pertuzumab (THP) in HER2+ stage II-III…

Prof. Nicholas Turner and colleagues presented findings from ZEST, the first Phase 3 trial evaluating MRD-guided therapy in breast cancer using circulating tumor DNA (ctDNA) surveillance.

At SABCS, Jean Wright presented a new analysis from the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 trials, providing critical insights into the role of tamoxifen for patients with “good risk”…

Prof. Sherko Kuemmel and the WSG Study Group presented key findings from the ADAPT HR+/HER2- chemotherapy trial, refining treatment strategies for high-risk HR+/HER2- early breast cancer.